Sequencing Platforms in Clinical Practice
In this section, I bridge clinical demand and requirements and platform choices, focusing on advanced NSCLC in Germany as a concrete reference: what testing can be performed in-house, and what might be more often handled through regional hubs or laboratory networks.
What this section covers
- Deployment models (in-house centre vs regional hub vs send-out)
- Assay strategy (DNA-only vs DNA+RNA, ctDNA integration)
- Operational constraints (turnaround, tissue efficiency, batching and throughput)
- Capacity & economics